In clinical trials, hospital staff copy patient data by hand into sponsors' trial databases, which YonaLink says takes about three minutes per data point. YonaLink, a company in Tel Aviv, built a platform that streams that data automatically from hospitals' electronic health records (EHR) into trial electronic data capture (EDC) systems.
The European Innovation Council granted €2,496,243 towards a €3.57 million project that validated the system in medical centres. In June 2024 YonaLink reported a pilot across 21 medical centres in the US and Israel that transferred 93% of requested data with 100% accuracy, and in October 2025 it added connections to Medidata Rave and Merative's Zelta. Its customer numbers and revenue are not public.
Company file
- Legal entity
- YonaLink Ltd., Tel Aviv, Israel
- Product
- EHR-to-EDC clinical trial data streaming platform
- Hospitals named
- Hadassah, Rambam, Sheba
- Integrations
- Medidata Rave, Merative Zelta (2025)
- Other EU work
- Partner in the EU-funded AI4LUNGS consortium (2024)
- EIC project
- YL System, 1 Sep 2022 to 28 Feb 2025, closed
- EIC funding
- Blended finance
Where YonaLink Stands Today
YonaLink's news page shows steady activity: Hadassah and Rambam medical centres adopted the platform in 2023, it joined the EU-funded AI4LUNGS consortium in 2024, launched an Israel Clinical Trial Network with state support in November 2024, and in October 2025 extended its connections to the Medidata Rave and Zelta trial systems and published an industry benchmark report. It names no pharmaceutical customers.
The Technology: From Patient Record to Trial Database
The pilot involved an oncology trial with 15 patients across 21 sites, transferring observations, medications, diagnoses, procedures and pathology. YonaLink says manual transfer takes about three minutes per data point. Eytan Ben Ami of Sheba Medical Center said in the announcement that "manual data transfer is outdated and leads to significant delays during clinical trials".
"Manual data transfer is outdated and leads to significant delays during clinical trials."
Eytan Ben Ami, Director of Clinical Research, Sheba Medical Center, June 2024What the EIC Project Promised, and What CORDIS Shows
The project promised "a pioneer clinical trial management system to automatically collect, review and analyse prospective clinical trial data". The CORDIS report describes validation with four medical centres in the first year, then in-field validation with "data being streamed from a range of MCs" and infrastructure scaled for performance. It gives no counts of trials, records or customers.
- A working streaming platformDeliveredValidated in medical centres.
- Accuracy at scaleDelivered21-centre pilot, 100% accuracy.
- Integration with major EDCsDeliveredRave and Zelta, 2025.
- Paying pharma customersNot shownNone named.
What Has Happened Since the Award
The Money
The award was blended finance; we found no EIC Fund investment. YonaLink raised $6 million in November 2022 to scale its growth. No later round has been announced, and Israeli company records were not accessible for this article.
What cannot be checked
Which trial sponsors pay for YonaLink, how many trials use it, its revenue and whether the EIC took equity are not public.
Why Europe Should Care
Faster, automated trial data entry would help sponsors and hospitals running trials in Europe. The EIC project was pitched as proof of readiness for the EU market. So far YonaLink's named sites are in Israel and the US, with EU work through a research consortium.
What the project promised
A system that automatically collects and analyses clinical trial data from hospitals.
What the record shows
A validated platform, a strong 21-centre pilot and major EDC integrations; no named paying customers.
The Verdict
The technology works; the market is unproven in public
YonaLink showed that hospital data can flow into trial databases accurately and connected to the systems sponsors use. The public record lacks the commercial side: who pays and how much. Its pilot also involved only 15 patients.
YonaLink has not been asked for comment for this article. It is based entirely on company statements and EU project data, linked throughout.
